Reducing risk with Health Economics (HE)
On the route to market, pharmaceutical or medical device products must reach many challenging milestones before the first patients will benefit from its therapeutic use and it becomes regularly reimbursed. For this reason, companies and their investors need to mitigate risk with accurate cost estimates on the specific stages of the market access process. Through a strategic partnership with LINK Medical, you will have access to our highly competent team that can help you accomplish this challenging task. We communicate actively with our customers to understand their business needs, and employ a variety of health economic tools and methods to provide full-service support throughout product development.
Getting the process right with Early Benefit Assessments
We utilize a variety of rigorous analytical methods for early assessments of pharmaceutical and medical device products, and keep them up-to-date as development progresses. To achieve this, we work in close collaboration with you to define the development phases of the regulatory and reimbursement strategies, as well as the milestones for allocating funding support. When bringing a new product to market, medical technology companies must present models of cost-effectiveness, cost-utility and cost-benefit to compare their products to standard treatments and devices on the market. Our uniquely talented staff have the deep understanding and experience to develop impactful health economic models that will support your entry into the market.
Creating market success
Obtaining reimbursement can often be a long-term project and success depends on various terms and regulations. Our experts can advise and guide you through the opportunities and potential risks of different reimbursement strategies. Our key local knowledge of markets across Northern Europe ensures that the reimbursement applications we produce adhere to all requirements and submission deadlines of local health authorities. Our team is highly experienced in the execution of every required step before launching a new commercial operation.
The value of Real World Evidence (RWE)
Real World Evidence (RWE) is an increasingly crucial component of benefit, risk and value demonstration, particularly for cases where the collection of data via traditional routes is difficult. These challenging studies can involve innovative medical device products, advanced medicinal therapies, or treatments for orphan and rare diseases. Our RWE services accelerate clinical development by providing indication prioritization along with faster and smaller randomized control trials (RCTs). Our iterative approach to evidence generation and early value proposition will ensure that your product reaches the market as soon as possible. In the post-marketing stage, we offer life cycle management services that maximize the value of your product after loss of exclusivity.
To find out more about how effective use of RWE and HE analyses can accelerate your product development, contact our Head of Department, Beate Bjørnstad Løkke at email@example.com.
Overview of RWE and HE services:
- Reimbursement applications for pharmaceutical products and medical devices
- Health Economic models
- Budget impact models
- Burden of illness studies
- Guidance on market access environment
- Real World Evidence and registry studies
- HTA/STA assessment and appraisal
- Literature reviews
Head of Department
Beate is the Director for our Market Access team, she has 5+ years of health economics (HE), market access (MA) and real world evidence (RWE) experience, covering therapeutic areas such as oncology, neurology, and immunology. She has hands on experience in Project management in HE, MA, and RWE projects, as well as strategic market access, advice within pharmaceuticals and medical device product life-cycle in addition to experience with developing health economic models.
Beate Løkke, holds a master of Health Economics, Policy and Management (Mphil) from the University of Oslo, with specialization within economic evaluation.
Contact via email